Key Points
- Director Harpreet Grewal sold 186 shares of Penumbra on January 6 at an average price of $312.64 for $58,151.04, reducing his stake by 2.21% to 8,230 shares.
- Penumbra beat recent quarterly estimates, reporting $0.97 EPS vs. $0.90 expected and $354.69 million in revenue (up 17.8% year‑over‑year), with a net margin of 12.3% and ROE of 11.35%.
- Analysts are generally bullish—multiple firms have raised ratings/targets (Citigroup, Needham, Canaccord), the consensus is a "Moderate Buy" with an average target of $340.40.
Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Harpreet Grewal sold 186 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total transaction of $58,151.04. Following the completion of the sale, the director owned 8,230 shares of the company's stock, valued at approximately $2,573,027.20. The trade was a 2.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Harpreet Grewal also recently made the following trade(s):
- On Tuesday, December 2nd, Harpreet Grewal sold 100 shares of Penumbra stock. The stock was sold at an average price of $292.98, for a total value of $29,298.00.
- On Tuesday, November 4th, Harpreet Grewal sold 186 shares of Penumbra stock. The shares were sold at an average price of $227.58, for a total transaction of $42,329.88.
- On Tuesday, November 4th, Harpreet Grewal sold 186 shares of Penumbra stock. The shares were sold at an average price of $227.58, for a total value of $42,329.88.
Penumbra Stock Performance
Penumbra stock opened at $315.47 on Friday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $321.38. The stock has a 50-day simple moving average of $293.26 and a 200 day simple moving average of $266.53. The stock has a market capitalization of $12.35 billion, a price-to-earnings ratio of 75.47, a P/E/G ratio of 1.93 and a beta of 0.71. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02.
Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.07. The firm had revenue of $354.69 million during the quarter, compared to analysts' expectations of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. Penumbra's revenue was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.85 EPS. On average, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of PEN. Royal Bank of Canada increased its holdings in shares of Penumbra by 35.8% during the 1st quarter. Royal Bank of Canada now owns 19,332 shares of the company's stock worth $5,169,000 after acquiring an additional 5,092 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Penumbra during the first quarter valued at approximately $656,000. Woodline Partners LP lifted its holdings in shares of Penumbra by 476.1% in the 1st quarter. Woodline Partners LP now owns 145,881 shares of the company's stock worth $39,010,000 after purchasing an additional 120,558 shares in the last quarter. Bayforest Capital Ltd grew its position in Penumbra by 35.9% in the 1st quarter. Bayforest Capital Ltd now owns 1,431 shares of the company's stock valued at $383,000 after purchasing an additional 378 shares during the period. Finally, Glenview Trust co acquired a new position in shares of Penumbra during the first quarter valued at about $230,000. 88.88% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
PEN has been the topic of several recent research reports. Citigroup raised shares of Penumbra from a "neutral" rating to a "buy" rating and raised their target price for the company from $285.00 to $350.00 in a research note on Thursday, December 11th. Canaccord Genuity Group increased their price objective on shares of Penumbra from $355.00 to $359.00 and gave the company a "buy" rating in a report on Wednesday, December 17th. Needham & Company LLC raised their price objective on shares of Penumbra from $326.00 to $388.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. Wall Street Zen raised shares of Penumbra from a "hold" rating to a "buy" rating in a report on Saturday, December 20th. Finally, Evercore ISI reissued an "outperform" rating and issued a $340.00 price target on shares of Penumbra in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $340.40.
Get Our Latest Analysis on Penumbra
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
